DBV Technologies S.A.
DBVT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for DBVT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DBVT
DBV Technologies S.A. is a clinical-stage biopharmaceutical company developing the Viaskin Peanut patch for peanut allergy in children aged 4 to 7, with a BLA submission planned for 2026 and Phase 3 trials ongoing.
Key risk: Cash runway limited to Q3 2027
BioSniper Score
Based on 6 of 6 signals
Market Cap
$850.9M
Cash Runway
10.4 moLead Asset
Viaskin Milk (Phase 3)
Next Catalyst
Phase3_Topline · May 1, 2028Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 15 clinical trials · 2 catalysts for DBV Technologies S.A..
DBV Technologies S.A. is a clinical-stage biopharmaceutical company developing the Viaskin Peanut patch for peanut allergy in children aged 4 to 7, with a BLA submission planned for 2026 and Phase 3 trials ongoing.
- Cash & equivalents of $174.9M as of 2026-06-30 [sec].
- Total revenue of $0.7M and net loss of $50.4M for the six months ended 2026-06-30 [sec].
- FDA confirmed safety data requirements for Viaskin Peanut BLA in children aged 4-7 in March 2025, providing a clear path to submission [sec_mda · as of 2026-04-30].
- Management estimates sufficient funding into Q3 2027 as of 2026-07-16 [sec_mda · as of 2026-07-16].
- Phase 3 topline results for dbv712 expected in 2028 and 2029 [upcoming catalysts].
What works
- FDA alignment on safety data requirements for Viaskin Peanut BLA in children 4-7 provides a clear regulatory path [sec_mda · as of 2026-04-30].
- Cash position of $174.9M as of 2026-06-30 and management guidance of funding into Q3 2027 support near-term operations [sec_mda · as of 2026-07-16].
- Pre-commercial inventory build-up of $16.1M indicates readiness for potential FDA approval [sec_mda · as of 2026-03-26].
What to weigh
- Net loss of $50.4M for the six months ended 2026-06-30 reflects ongoing operating losses [sec].
- Cash runway only extends into Q3 2027, with no guarantee of additional financing [sec_mda · as of 2026-07-16].
- BLA submission timing revised from Q2 to Q3 2026, indicating potential delays [sec_mda · as of 2026-07-16].
- ATM sales program expired in April 2026, limiting near-term equity financing flexibility [sec_mda · as of 2026-07-16].
From the filings
Quoted directly from source documents.
FDA confirmed safety data requirements for Viaskin Peanut BLA in children 4-7
“In March 2025, the FDA confirmed the safety data requirements to support the planned Biologics License Application for Viaskin Peanut in children aged 4 to 7 if approved, providing a clear and executable path toward submission.”
SEC MD&A · April 30, 2026
Cash and cash equivalents of $229.2M as of March 31, 2026
“As of March 31, 2026, Cash & Cash Equivalents are $229.2 million.”
SEC MD&A · April 30, 2026
Management estimates funding into Q3 2027
“management estimates that the Company has sufficient funding to support its operations for at least twelve months from the date of issuance of this Form 10‑Q, into the third quarter of 2027.”
SEC MD&A · July 16, 2026
Pre-commercial inventory of $16.1M for commercial readiness
“The caption Pre-Commercial Inventory of $16.1 million reflects efforts launched by the company in inventory build-up to support commercial readiness in anticipation of potential FDA approval (written down as they do not meet recognition criteria).”
SEC MD&A · March 26, 2026
Catalyst timeline
- 2028-05-01 · Phase3_Topline · dbv712 — Phase 3 Topline: A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous I — First Phase 3 topline readout for dbv712 safety study; results will inform regulatory and clinical path.
- 2029-10-01 · Phase3_Topline · dbv712 — Phase 3 Topline: A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of E — Second Phase 3 topline readout for dbv712 efficacy and safety study; pivotal for potential approval.
Risks & what to watch (4)›
Key risks
- Cash runway limited to Q3 2027 — Management estimates funding only into Q3 2027; additional capital may be needed [sec_mda · as of 2026-07-16].
- BLA submission delay risk — BLA submission for Viaskin Peanut revised from Q2 to Q3 2026 [sec_mda · as of 2026-07-16].
- ATM program expired — Sales agreement expired April 2026; no new registration statement effective yet [sec_mda · as of 2026-07-16].
- No approved product revenue — Total revenue only $0.7M for six months ended 2026-06-30; relies on external financing [sec].
What to watch
- BLA submission for Viaskin Peanut in children 4-7, expected Q3 2026 [sec_mda · as of 2026-07-16].
- Phase 3 topline results for dbv712 expected in 2028 and 2029 [upcoming catalysts].
- Cash burn rate and any new financing activities to extend runway beyond Q3 2027 [sec_mda · as of 2026-07-16].
- FDA decision on Viaskin Peanut BLA, if submitted, and potential commercial launch [sec_mda · as of 2026-04-30].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run DBV Technologies S.A. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available DBV Technologies S.A. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
10.4 months
D/E 0.39 · 0% dilution
Lead: Phase 3
2 candidates
2 upcoming, next in ~610d
0 buys · 1 sell (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
66
Total value held
$275.8M
| Holder | Shares | Value |
|---|---|---|
| mpm bioimpact llc | 5,213,361 | $108.9M |
| perceptive advisors llc | 1,928,782 | $40.3M |
| baker bros. advisors lp | 1,461,425 | $30.5M |
| adar1 capital management, llc | 1,012,866 | $21.2M |
| redmile group, llc | 491,340 | $10.3M |
| millennium management llc | 318,959 | $6.7M |
| atika capital management llc | 271,300 | $5.7M |
| elmind capital, lp | 265,000 | $5.5M |
| balyasny asset management l.p. | 233,429 | $4.9M |
| ameriprise financial inc | 231,417 | $4.8M |
Showing top 10 of 66 institutional holders of DBV Technologies S.A.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 3.1%
- Days to cover
- 7.7
- Shares short
- 1,814,983
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DBVT short interestGovernance
Frequently asked questions
What is the AI investment thesis for DBV Technologies S.A.?
DBV Technologies S.A. is a clinical-stage biopharmaceutical company developing the Viaskin Peanut patch for peanut allergy in children aged 4 to 7, with a BLA submission planned for 2026 and Phase 3 trials ongoing.
What is DBV Technologies S.A.'s lead drug candidate?
DBV Technologies S.A.'s most advanced tracked candidate is Viaskin Milk (Phase 3) for Peanut Allergy.
What is DBV Technologies S.A.'s next catalyst?
DBV Technologies S.A.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous I" — expected May 1, 2028.
Who is the CEO of DBV Technologies S.A.?
Mr. Daniel Tassé is the chief executive officer of DBV Technologies S.A. (DBVT).
Where is DBV Technologies S.A. headquartered?
DBV Technologies S.A. (DBVT) is headquartered in Châtillon, France.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.